Pioneer of prostate cancer: past, present and the future of FOXA1
Protein & Cell
;
(12): 29-38, 2021.
Artículo
en Inglés
| WPRIM
| ID: wpr-880916
ABSTRACT
Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American men. While androgen deprivation has remained as the cornerstone of prostate cancer treatment, resistance ensues leading to lethal disease. Forkhead box A1 (FOXA1) encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors. Through direct interactions with the Androgen Receptor (AR), FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells. FOXA1 also possesses an AR-independent role of regulating epithelial-to-mesenchymal transition (EMT). In prostate cancer, mutations converge onto the coding sequence and cis-regulatory elements (CREs) of FOXA1, leading to functional alterations. In addition, FOXA1 activity in prostate cancer can be modulated post-translationally through various mechanisms such as LSD1-mediated protein demethylation. In this review, we describe the latest discoveries related to the function and regulation of FOXA1 in prostate cancer, pointing to their relevance to guide future clinical interventions.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Próstata
/
Neoplasias de la Próstata
/
Unión Proteica
/
Transcripción Genética
/
Histonas
/
Transducción de Señal
/
Receptores Androgénicos
/
Regulación Neoplásica de la Expresión Génica
/
Procesamiento Proteico-Postraduccional
/
Secuencia de Aminoácidos
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Protein & Cell
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS